{"PMC2811155": {"PMC3549971_2": {"context": "Previously examined Parkin mutations that occur in PD patients display a range of mitochondrial translocation activities but most fail to induce mitophagy (Geisler et al., 2010; Matsuda et al., 2010; Narendra et al., 2010).\n", "support": ["Since disease-causing mutations in PINK1 or Parkin disrupt this pathway, patients with these mutations may not be able to clean up their damaged mitochondria, leading to the neuronal damage typical of parkinsonism.\n", "In this pathway, PINK1 acts as a flag that accumulates on dysfunctional mitochondria and then signals to Parkin, which tags these mitochondria for destruction.\n"]}, "PMC3549971_1": {"context": "PINK1 recruits Parkin to mitochondria via its kinase activity (Geisler et al., 2010; Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al., 2010).\n", "support": ["In this pathway, PINK1 acts as a flag that accumulates on dysfunctional mitochondria and then signals to Parkin, which tags these mitochondria for destruction.\n", "A kinase-deficient (KD) version of PINK1 [28] also failed to reconstitute Parkin recruitment to mitochondria (Figure 3A and 3B).\n"]}, "PMC3010068_2": {"context": "To achieve this, we applied two Parkin mutants: ParkinR275W, which translocates to depolarized mitochondria but fails to induce mitophagy; and ParkinC441R, which fails to translocate to mitochondria (Narendra et al., 2010).\n", "support": ["Although expression of Parkin R275W was moderately less than wild type, it also increases localization in the membrane fraction and decreases in the supernatant upon CCCP treatment, consistent with the mitochondrial translocation seen for this mutation by confocal microscopy (Figure 9C).\n", "Although under control conditions some mutants formed visible aggregates (Figure S8D), no mutant, including R275W, colocalized with mitochondria (Figure 9B and Figure S8E).\n", "Interestingly, the R275W mutation in RING1 also exhibited a severe deficit in mitophagy (4.0\u00b14%) (Figure 9D and 9E) even though it appears to largely retain its ability to translocate to uncoupled mitochondria (Figure 9A and 9B).\n"]}, "PMC3010068_3": {"context": "PINK1, a mitochondrial kinase, is essential for the Parkin translocation to depolarized mitochondria and for Parkin-mediated mitophagy (Geisler et al., 2010; Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al., 2010).\n", "support": ["PINK1 accumulation on mitochondria is both necessary and sufficient for Parkin recruitment to mitochondria, and disease- causing mutations in PINK1 and Parkin disrupt Parkin recruitment and Parkin- induced mitophagy at distinct steps. \n"]}, "PMC3010068_1": {"context": "Consistent with genetic studies in flies that indicated that they work in the same pathway, Parkin translocation and mitophagy induction require PINK1 activity (Geisler et al., 2010; Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al., 2010).\n", "support": ["Consistent with genetic studies in Drosophila, these findings show that Parkin translocation to depolarized mitochondria and Parkin-induced mitophagy are downstream of PINK1 expression, whereas PINK1 accumulation in response to depolarization is upstream of Parkin recruitment.\n"]}, "PMC2995166_8": {"context": "When we treated HeLa cells stably expressing YFP-Parkin with MG132 for 8 h to accumulate the 52-kD PINK1 (Fig. 1 c; Narendra et al., 2010)\n", "support": ["Cells treated with vehicle or 250 nM AP21967 for 8 h were scored for mCherry-Parkin in puncta characteristic of mitochondria in \u2265150 cells in three or more independent experiments.\n", "When MG132 is added during the final hour of treatment in HeLa cells treated with vehicle, an \u223c52-kDa band appears, consistent with the cleavage product of full-length Parkin described in previous reports [22],[28],[30] (Figure 2A, lane 1 vs. lane 2).\n"]}, "PMC3291531_2": {"context": "A decline in mitochondrial membrane-potential induced by the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) was reported to activate the PINK1/Parkin pathway [13], [14], [39].\n", "support": ["When HeLa cells are treated with CCCP, which depolarizes mitochondria by increasing membrane permeability to H+, a large increase in endogenous full-length PINK1 (\u223c63 kDa) is seen beginning by 30 min and continuing for at least 3 h (Figure 1A).\n"]}, "PMC3010068_4": {"context": "In contrast to inhibition of transcription, inhibition of translation by treatment with cycloheximide (CHX) prevents both the CCCP-dependent induction of PINK1 expression and Parkin translocation to CCCP-uncoupled mitochondria (Narendra et al., 2010).\n", "support": ["Although these findings do not prove new PINK1 synthesis is required for Parkin recruitment (cycloheximide blocks de novo synthesis of all proteins and thus may inhibit Parkin recruitment independently of PINK1 accumulation), they suggest that PINK1 accumulation and Parkin recruitment may be casually related.\n", "A 90-min treatment with cycloheximide, likewise, blocked Parkin recruitment to depolarized mitochondria by confocal microscopy (96.0\u00b13.5% vs. 11.3\u00b14.2%) (Figure 7C and 7D).\n"]}, "PMC3010068_5": {"context": "M17 neuroblastoma carrying small hairpin RNA (shRNA) for control or PINK1 (Narendra et al., 2010)\n", "support": ["To verify that the \u223c63-kDa band is in fact PINK1, we immunoblotted for endogenous PINK1 in M17 cells stably transduced with control short hairpin RNA (shRNA) or PINK shRNA.\n"]}, "PMC3291531_1": {"context": "Miro protein level might be regulated by PINK1 and possibly Parkin, which tends to work together with PINK1 in a common pathway [3]\u2013[5], [39].\n", "support": ["Previous studies in flies and mice, and in human cells suggest that PINK1 and Parkin are part of a common pathway that protects against damaged mitochondria; these organelles power the cell when healthy but can produce harmful reactive oxygen species when damaged.\n"]}, "PMC3010068_6": {"context": "The plasmids carrying shRNA sequences for DRP1, Mito-YFP, mCherry-Parkin, YFP-Parkin (wild type, R275W, C441R), and Mfn2-YFP have been described previously (Karbowski et al., 2007; Narendra et al., 2008, 2010).\n", "support": ["To verify that the \u223c63-kDa band is in fact PINK1, we immunoblotted for endogenous PINK1 in M17 cells stably transduced with control short hairpin RNA (shRNA) or PINK shRNA.\n"]}, "PMC3000346_2": {"context": "This translocation of Parkin requires the function of PINK1, which is stabilized and accumulates on damaged mitochondria [12].\n", "support": ["In this model, mitochondrial PINK1 is rapidly turned over on bioenergetically well-coupled mitochondria by proteolysis, but is selectively stabilized on mitochondria with low membrane potential.\n"]}, "PMC2995166_3": {"context": "ectopic and endogenous PINK1 have been reported to span the outer mitochondrial membrane with the C-terminal kinase region facing the cytosol poised to induce Parkin translocation (Zhou et al., 2008; Narendra et al., 2010).\n", "support": ["Consistent with results from a recent study of PINK1's topology when it is ectopically expressed [22], we found that the kinase domain of endogenous PINK1 faces the cytosol following depolarization (Figure S1E).\n", "These data suggest that PINK1 promotes mitophagy in the context of endogenous levels of Parkin.\n", "Parkin is selectively recruited from the cytosol to damaged mitochondria to trigger their autophagy.\n", "Our results suggest that full-length mitochondrial PINK1 is the active form in the PINK1/Parkin pathway, and that cleavage of PINK1 into an unstable cytosolic form maintains low levels of PINK1 on healthy mitochondria in order to suppress the PINK1/Parkin pathway in the absence of mitochondrial damage.\n", "Parkin-dependent mitophagy is reconstituted by exogenous PINK1 expression in the PINK\u2212/\u2212 MEFs, with 65.5\u00b15.0% of reconstituted PINK\u2212/\u2212 cells displaying undetectable mitochondria following CCCP treatment\n"]}, "PMC2995166_2": {"context": "Although endogenous PINK1 protein expression is constitutively low owing to rapid turnover, PINK1 proteolysis is inhibited by mitochondrial uncoupling, allowing a robust increase in expression when a mitochondrion is damaged and loses membrane potential (Lin and Kang, 2008; Matsuda et al., 2010; Narendra et al., 2010).\n", "support": ["Here, we show that expression of PINK1 on individual mitochondria is regulated by voltage- dependent proteolysis to maintain low levels of PINK1 on healthy, polarized mitochondria, while facilitating the rapid accumulation of PINK1 on mitochondria that sustain damage. \n", "In this model, mitochondrial PINK1 is rapidly turned over on bioenergetically well-coupled mitochondria by proteolysis, but is selectively stabilized on mitochondria with low membrane potential. Se\n", "However, OPA3-PINK1 \u03941-110-YFP, which does not display voltage dependent proteolysis, recruits mCherry-Parkin to mitochondria in 98\u00b11.8% of cells in the absence of CCCP (Figure 6D and 6E)\n", "This selective accumulation is achieved by a novel mechanism, in which PINK1 is constitutively synthesized and imported into all mitochondria, but cleaved from healthy mitochondria by voltage-sensitive proteolysis (Figure S9).\n", "Remarkably, levels of endogenous mitochondrial PINK1 respond robustly to changes in mitochondrial membrane potential.\n"]}, "PMC3000346_1": {"context": "PINK1 and Parkin have also been suggested to collaborate to form a mitochondrial quality control system [11], [12].\n", "support": ["Recent studies have linked Parkin and PINK1 in a pathway critical for the maintenance of mitochondrial integrity and function.\n", "Loss-of-function mutations in PINK1 and Parkin cause parkinsonism in humans and mitochondrial dysfunction in model organisms.\n"]}, "PMC2995166_1": {"context": "Upon mitochondrial damage or uncoupling, Parkin relocalizes to mitochondria and can mediate the autophagic elimination of damaged mitochondria (Narendra et al., 2008), which is dependent on PINK1 kinase activity (Geisler et al., 2010; Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al., 2010).\n", "support": ["We recently reported that the Parkinson disease-linked E3 ubiquitin ligase, Parkin, is selectively recruited to dysfunctional mitochondria with low membrane potential to promote their autophagic degradation, suggesting that a deficiency of mitochondrial quality control may underlie the observed mitochondrial dysfunction in Parkin knockout Drosophila and mice [11]\u2013[15],[17],[21].\n", "PINK1 accumulation on mitochondria is both necessary and sufficient for Parkin recruitment to mitochondria, and disease- causing mutations in PINK1 and Parkin disrupt Parkin recruitment and Parkin- induced mitophagy at distinct steps. \n", "In this pathway, PINK1 acts as a flag that accumulates on dysfunctional mitochondria and then signals to Parkin, which tags these mitochondria for destruction.\n", "Since disease-causing mutations in PINK1 or Parkin disrupt this pathway, patients with these mutations may not be able to clean up their damaged mitochondria, leading to the neuronal damage typical of parkinsonism.\n", "In this model, PINK1 and Parkin form a pathway for sensing and selectively eliminating damaged mitochondria from the mitochondrial network.\n"]}, "PMC2995166_5": {"context": "proteosome-independent proteolysis yields a 52-kD form of PINK1 that is subsequently degraded by the proteosome (Narendra et al., 2010).\n", "support": ["Full- length PINK1 (\u223c63 kDa), which is anchored in the mitochondrial membrane, is proteolytically cleaved into an \u223c52-kDa cytosolic fragment that can be degraded by the proteasome [22],[28]\u2013[30]. \n", "When MG132 is added during the final hour of treatment in HeLa cells treated with vehicle, an \u223c52-kDa band appears, consistent with the cleavage product of full-length Parkin described in previous reports [22],[28],[30] (Figure 2A, lane 1 vs. lane 2).\n", "Taken together, these results support a two-step model for the processing of PINK1: first, full-length PINK1 is cleaved into the \u223c52-kDa short form in a voltage-dependent, proteasome-independent manner, and second, the short form of PINK1 is rapidly degraded by the proteasome (Figure 2B).\n", "Full-length mitochondrial PINK1 (\u223c63 kDa) is cleaved into a short \u223c52-kDa form, but the short, primarily cytosolic form is unstable, raising the questions: why is PINK1 found both on the mitochondria and in the cytosol, and which form of PINK1 is active in the PINK1/Parkin pathway [22],[28]\u2013[30].\n", "Although the intramembrane serine protease Rhomboid-7 appears to be required for PINK1 cleavage in Drosophila [31], our results suggest that PARL, its mammalian ortholog, is not required for PINK1 cleavage in mammalian cells.\n"]}, "PMC2995166_4": {"context": "owing to insufficient knockdown of endogenous PARL in HeLa cells and to insufficient expression of ectopic PINK1 in PARL knockout (KO) mouse embryonic fibroblasts (MEFs; Narendra et al., 2010).\n", "support": ["Although endogenous PARL could not be detected in HeLa cells, PARL shRNA inhibited expression of overexpressed PARL (Figure S2A and S2B).\n", "We found that the \u223c63-kDa band increases following CCCP treatment in control shRNA cells, but does not increase in the PINK1 shRNA cells, demonstrating that this \u223c63-kDa band is endogenous PINK1 (Figure 1B).\n", "Endogenous PINK1 accumulates similarly in HeLa cells, which display little or no endogenous Parkin expression, and HeLa cells stably expressing YFP-Parkin (Figure S2D).\n", "These data suggest that PINK1 promotes mitophagy in the context of endogenous levels of Parkin.\n", "As we found previously [21], expression of wild-type Parkin in HeLa cells that do not detectably express endogenous Parkin completely eliminates mitochondria in greater than half of the cells (59.0\u00b115.1%) following treatment with CCCP for 24 h (Figure 9D and 9E).\n"]}, "PMC2995477_1": {"context": "We and others have previously demonstrated that endogenous PINK1 behaves similarly to the overexpressed PINK1 counterparts in that PINK1 FL accumulates under valinomycin treatment and PINK1 \u03941 and \u03942 accumulate under proteasome inhibitor treatment [9,12,22]\n", "support": ["When HeLa cells are treated with CCCP, which depolarizes mitochondria by increasing membrane permeability to H+, a large increase in endogenous full-length PINK1 (\u223c63 kDa) is seen beginning by 30 min and continuing for at least 3 h (Figure 1A).\n", "his \u223c63-kDa band also increases in the mitochondria-rich membrane fraction following treatment with valinomycin, which, unlike CCCP, depolarizes mitochondria by permeabilizing the membrane to K+ (Figure S1A).\n"]}, "PMC2995166_6": {"context": "the CCCP-stabilized form of PINK1 that localizes to the outer mitochondrial membrane facing the cytosol (Narendra et al., 2010),\n", "support": ["Likewise, PINK1-V5 levels were similar in PARL\u2212/\u2212 and PARL+/+ MEFs, under basal conditions and following depolarization with CCCP (Figure S2C).\n", "Together, these results suggest that PARL is dispensable for PINK1 cleavage.\n"]}, "PMC2995166_7": {"context": "experimentally stabilized PINK1 on the mitochondrial outer membrane recruits Parkin even in the absence of mitochondrial uncoupling (Narendra et al., 2010).\n", "support": ["We found that, similar to YFP-Parkin [21], PINK1-YFP accumulates selectively on mitochondria with low membrane potential, demonstrating that PINK1 is selectively stabilized on the depolarized mitochondria within a bioenergetically diverse population of mitochondria (Figure 1E and 1F).\n"]}, "PMC2995477_2": {"context": "mitophagy of damaged mitochondria [22,29-32].\n", "support": ["Here, we show that full-length PINK1 accumulates selectively on dysfunctional mitochondria, and that Parkin recruitment to depolarized mitochondria and subsequent Parkin-induced mitophagy are strictly dependent on PINK1's mitochondrial targeting signal and depolarization-induced accumulation.\n"]}, "PMC3020954_3": {"context": "PINK1 kinase activity is required for many Parkin functions and Parkin acts downstream of PINK1 [11]\n", "support": ["PINK1 accumulation on mitochondria is both necessary and sufficient for Parkin recruitment to mitochondria, and disease- causing mutations in PINK1 and Parkin disrupt Parkin recruitment and Parkin- induced mitophagy at distinct steps.\n", "Interestingly, overexpression of Parkin can partially compensate for PINK1 loss, but PINK1 overexpression cannot compensate for Parkin loss, suggesting that PINK1 functions upstream of Parkin in a common pathway.\n", "Together, these results show that PINK1 accumulation is upstream of Parkin recruitment to depolarized mitochondria and independent of Parkin expression.\n"]}, "PMC3050809_3": {"context": "Several studies reported that mitochondrial stress, such as exposure to membrane potential inhibitors, initiates the PINK1/Parkin mitophagy pathway [14], [15], [16], [17], [20], [28].\n", "support": ["Although the proximate cause of these abnormalities in PINK1 null cells remains obscure, one explanation may be the failure of PINK1/Parkin pathway to eliminate oxidatively damaged mitochondria, which accumulate over time as a natural consequence of metabolism and other cellular stresses.\n"]}, "PMC3050809_2": {"context": "a deficit in mitophagy leads to accumulation of dysfunctional mitochondria in the cell [14], [15], [16], [17].\n", "support": ["Since disease-causing mutations in PINK1 or Parkin disrupt this pathway, patients with these mutations may not be able to clean up their damaged mitochondria, leading to the neuronal damage typical of parkinsonism.\n", "We found that Parkin-induced mitophagy is also dependent on PINK1 expression in the M17 human neuroblastoma cell line.\n", "These results suggest that PINK1 is necessary for the mitophagy of depolarized mitochondria following overexpression of Parkin.\n", "Alternatively, Parkin may serve other functions in the cell that are independent of PINK1 and protect against mitochondrial dysfunction indirectly; or Parkin may function to some degree upon overexpression independently of mitochondrial docking, perhaps effecting mitophagy or other mitochondrial changes from the cytosolic compartmen\n"]}, "PMC3020954_1": {"context": "PINK1 is required for recruitment of Parkin to mitochondria with impaired membrane potential [11], [12].\n", "support": ["PINK1 accumulation on mitochondria is both necessary and sufficient for Parkin recruitment to mitochondria, and disease- causing mutations in PINK1 and Parkin disrupt Parkin recruitment and Parkin- induced mitophagy at distinct steps. \n"]}, "PMC3050809_4": {"context": "the \u201cincreased\u201d mfn levels in pink1 or parkin knockdown flies may reflect an increase in mitochondrial biogenesis in these mutants [17].\n", "support": ["These results are consistent with endogenous PINK1 promoting mitochondrial degradation in the context of continued (or increased) mitochondrial biogenesis [37],[38].\n", "These data suggest that PINK1 promotes mitophagy in the context of endogenous levels of Parkin.\n", "Additionally, these results suggest that the selective turnover of dysfunctional mitochondria may be balanced by the biogenesis of new mitochondria, allowing exchange of damaged, dysfunctional mitochondria for healthy, functional mitochondria.\n"]}}, "PMC2848616": {"PMC4154524_3": {"context": "Interestingly, this treatment induced autophagy marked by increased expression of Atg 7, Atg5-Atg12, decrease in p62, no modification of LC3 expression and controversial results surrounding LC3-II expression in PDAPP and 3xTg-AD mice [45,46].\n", "support": ["In contrast, no differences in LC3-II/\u03b2-actin ratios were observed between control- and rapamycin-treated non-transgenic littermates ( Fig. 3a\u2013b ), suggesting that rapamycin may induce autophagy as a response to high A\u03b2 levels in hippocampi of transgenic PDAPP mice.\n", "In agreement with the expected induction of autophagy by rapamycin-mediated inhibition of mTOR, LC3-II/\u03b2-actin ratios in hippocampi of rapamycin-treated PDAPP mice were significantly decreased ( Fig. 3a\u2013b ).\n"]}, "PMC4154524_1": {"context": "Furthermore, many studies have revealed that the stimulation of autophagy can reduce A\u03b2 accumulation and alleviate memory deficits in transgenic AD mice [45-48].\n", "support": ["Our data suggest that the reduction in A\u03b242 levels and the improvement in cognitive function in rapamycin-treated PDAPP mice may be a consequence of the induction of autophagy in hippocampus ( Fig. 3 ) by high levels of A\u03b2 in PDAPP transgenic brains. \n"]}, "PMC3509553_3": {"context": "autophagy may be necessary during inhibition of mTOR signaling to improve cognitive function, limit A\u03b2 toxicity\n", "support": ["In addition, rapamycin treatment did not induce autophagy and did not affect levels of endogenous A\u03b2 in non-transgenic mice, suggesting that autophagy may have a key role in reducing A\u03b242 in transgenic PDAPP brains. \n", "As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in A\u03b2 and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of A\u03b2.\n"]}, "PMC3776211_2": {"context": "Rapamycin induced inhibition of mTORC1 has also been shown to decrease beta-amyloid expression by increasing the rate of autophagy [18,29].\n", "support": ["As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in A\u03b2 and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of A\u03b2.\n", "Taken together, our results suggest that autophagy is induced by rapamycin-mediated mTOR inhibition specifically as a response to high A\u03b2 levels in hippocampi of rapamycin-treated PDAPP mice.\n"]}, "PMC3509553_2": {"context": "In addition, mTOR inhibition that can lead to autophagy in murine models of AD has been shown to improve memory and limit A\u03b2 levels [93].\n", "support": ["Although the differences in performance between control-fed and rapamycin-fed non- transgenic groups were not significant, they may suggest that changes in pathways different from autophagy (such as effects on the regulation of protein synthesis) as a result of long-term mTOR inhibition may have a positive effect on learning and memory. \n"]}, "PMC3776211_1": {"context": "There is also evidence of an association between mTOR signalling and beta-amyloid, although the nature of the association is uncertain [18,28,29].\n", "support": ["Consistent with a key role for high levels of A\u03b2 in the activation of autophagy when mTOR activity is reduced, rapamycin did not induce autophagy in brains of rapamycin-treated non-transgenic mice, in which levels of endogenous A\u03b2 are much lower than those in PDAPP transgenic brains\n"]}, "PMC3182203_2": {"context": "We, and others, have previously shown that rapamycin reduces soluble A\u03b2 and tau pathology and the associated early cognitive deficits in 6-month-old transgenic mice [29], [32].\n", "support": ["Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n", "Rapamycin, already used in clinical settings, may be a potentially effective therapeutic agent for the treatment of AD.\n"]}, "PMC3182203_3": {"context": "Data in apparent contradiction to each other have been also reported by others [5], [29], [32], [71], [72], [73], [74], [75].\n", "support": ["Thus, our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can lower A\u03b2 levels and slow or block AD progression in a transgenic mouse model of the disease, possibly by stimulating autophagy.\n"]}, "PMC3509553_1": {"context": "Under some conditions, autophagy can offer cytoprotection during neurodegenerative disorders [92,93].\n", "support": ["Taken together, our results suggest that autophagy is induced by rapamycin-mediated mTOR inhibition specifically as a response to high A\u03b2 levels in hippocampi of rapamycin-treated PDAPP mice.\n"]}, "PMC3776211_4": {"context": "The strong effect of Rapamycin on these cellular functions also identifies mechanisms responsible for the beneficial effect of the drug in the transgenic model of AD [29].\n", "support": ["Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC4599244_1": {"context": "Furthermore, inhibition of mTOR by rapamycin can slow or block AD progression in a transgenic mouse model of the disease [37].\n", "support": ["In summary, our data suggest that inhibition of mTOR by rapamycin[5], an intervention that extends lifespan in mice[5], [6], can slow or block AD progression in a transgenic mouse model of the disease.\n", "Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC4599244_2": {"context": "rapamycin also produces an improvement in age-associated cognitive functions in mouse[35-37].\n", "support": ["As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in A\u03b2 and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of A\u03b2.\n", "In summary, our data suggest that inhibition of mTOR by rapamycin[5], an intervention that extends lifespan in mice[5], [6], can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC2886067_1": {"context": "Autophagy has been shown to protect neurons from A\u03b2 induced cytotoxicity\n", "support": ["As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in A\u03b2 and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of A\u03b2\n"]}, "PMC5797541_3": {"context": "Rapamycin, a selective inhibitor of target-of-rapamycin complex 1 (TORC1) and thus modulator of the mTOR pathway activity, improved learning and memory and reduced A\u03b2 and tau pathology in the brains of AD mouse model (Caccamo et al., 2010; Spilman et al., 2010).\n", "support": ["In summary, our data suggest that inhibition of mTOR by rapamycin[5], an intervention that extends lifespan in mice[5], [6], can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC2886067_2": {"context": "pharmacological stimulation of autophagy can be beneficial and reduce A\u03b2 mediated toxicity\n", "support": ["These data indicate that inhibition of the mTOR pathway by long-term rapamycin treatment can reduce A\u03b242 levels in vivo and block or delay AD in mice. \n"]}, "PMC4399516_2": {"context": "mTOR, an inhibitor of autophagy, decreases the A\u03b2 clearance of the autophagy/lysosome system which accounts for the clearance of abnormal proteins.20,43 mTOR also modulates the metabolism of APP by regulating \u03b2- and \u03b3-secretase.\n", "support": ["The reduction in A\u03b242 in PDAPP brains did not likely arise from changes in production, since the abundance of C99, the C-terminal product of \u03b2-secretase cleavage of APP, as well the levels of expression of hAPP were unchanged by rapamycin ( Fig. 2f\u2013h ). \n"]}, "PMC4399516_3": {"context": "Additionally, mTOR, inhibitor of autophagy, is closely associated with the levels of A\u03b2.\n", "support": ["Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC6295637_1": {"context": "Furthermore, rapamycin administration improved memory functions in murine models of AD (Caccamo et al., 2010[13]; Majumder et al., 2012[48]; Spilman et al., 2010[75]).\n", "support": ["Although the differences in performance between control-fed and rapamycin-fed non- transgenic groups were not significant, they may suggest that changes in pathways different from autophagy (such as effects on the regulation of protein synthesis) as a result of long-term mTOR inhibition may have a positive effect on learning and memory. \n"]}, "PMC4399516_6": {"context": "Inhibition of mTOR by rapamycin retards cognitive deficits and reduces the abnormal hyperphosphorylation of tau by autophagy enhancement in AD models.\n", "support": ["Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n", "In summary, our data suggest that inhibition of mTOR by rapamycin[5], an intervention that extends lifespan in mice[5], [6], can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC2942840_1": {"context": "mTOR signaling was shown to be up-regulated in 7PA2 cells over-expressing mutant APP and in brains of another AD transgenic mouse, with rapamycin treatment reported as protective against behavioral decline\n", "support": ["Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC4399516_4": {"context": "Conversely, the activation of mTOR is likely to promote A\u03b2 production.\n", "support": ["These data indicate that inhibition of the mTOR pathway can reduce A\u03b242 levels in vivo and block or delay AD in mice. \n"]}, "PMC6295637_2": {"context": "increase autophagy and decrease the amyloid \u03b2 level in animal models of AD (Spilman et al., 2010[75]).\n", "support": ["Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n", "In summary, our data suggest that inhibition of mTOR by rapamycin[5], an intervention that extends lifespan in mice[5], [6], can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC6295637_3": {"context": "reduce cognitive deficits related to neurological disorders such as AD\n", "support": ["In summary, our data suggest that inhibition of mTOR by rapamycin[5], an intervention that extends lifespan in mice[5], [6], can slow or block AD progression in a transgenic mouse model of the disease.\n", "Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.\n"]}, "PMC4399516_5": {"context": "The striking similarity is the results from the insulin intervention and the inhibition of mTOR by rapamycin that rescue cognitive impairment and retard A\u03b2 pathology in AD animal models.\n", "support": ["In addition, the reduction in A\u03b242 did not likely arise from increased degradation, since levels of the two major A\u03b2-degrading activities, neprilysin (NEP)[35], and insulin-degrading enzyme (IDE)[38] were unchanged in brains of control- and rapamycin-fed PDAPP mice as well ( Fig. 2f, j\u2013k ). \n"]}, "PMC2942840_2": {"context": "although effects were mild\n", "support": ["Although the differences in performance between control-fed and rapamycin-fed non- transgenic groups were not significant, they may suggest that changes in pathways different from autophagy (such as effects on the regulation of protein synthesis) as a result of long-term mTOR inhibition may have a positive effect on learning and memory. \n"]}}, "PMC3442244": {"PMC4030114_4": {"context": "We identified 20 predominantly \u03b2-cell\u2013associated SNPs by 1) their significant effect on homeostasis model assessment (HOMA)-\u03b2 (\u03b2 < \u20130.008; P < 0.05) in the most recent Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) (12)\n", "support": ["We used the published MAGIC meta-analysis (up to 37,037 non-diabetic individuals) of HOMA indices of beta-cell function and insulin sensitivity5 as these traits were not included in the enlarged Metabochip study34.\n"]}, "PMC4030114_5": {"context": "We identified 10 predominantly IR\u2013related SNPs by 1) their significant association with HOMA-IR (P < 0.05) in the MAGIC data (12), 2)\n", "support": ["To gain a more complete picture of patterns of trait overlap, we first assessed the effect of T2D risk alleles on glycemic traits in European-descent meta- analyses from the MAGIC Investigators (Online Methods). \n"]}, "PMC4030114_1": {"context": "The DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium recently published the largest T2D GWAS meta-analysis to date (DIAGRAMv3), identifying many additional common variants associated with T2D and bringing the total number of independent T2D loci to 65 (12).\n", "support": ["Figure 1 presents the distribution of Z-scores from Stage 2, aligned to the risk allele from Stage 1, at a subset of 3,412 independent (CEU r2 < 0.05) T2D replication variants that excludes lead SNPs and possible proxies (CEU r2 \u2265 0.1) at the 63 newly discovered and established loci represented on Metabochip.\n", "Using simulations, based on parameter estimates from this mixture model, we estimated that 488 (95% confidence interval (CI) 456\u2013521) of the independent replication SNPs, in addition to the 63 newly discovered and established loci, are associated with T2D susceptibility. \n"]}, "PMC4030114_3": {"context": "In the present analyses, we updated these GRS  to include as many of the 65 index SNPs or their proxies as were available at the confirmed or newly identified loci from DIAGRAMv3 (12)\n", "support": ["Figure 1 presents the distribution of Z-scores from Stage 2, aligned to the risk allele from Stage 1, at a subset of 3,412 independent (CEU r2 < 0.05) T2D replication variants that excludes lead SNPs and possible proxies (CEU r2 \u2265 0.1) at the 63 newly discovered and established loci represented on Metabochip.\n", "Using simulations, based on parameter estimates from this mixture model, we estimated that 488 (95% confidence interval (CI) 456\u2013521) of the independent replication SNPs, in addition to the 63 newly discovered and established loci, are associated with T2D susceptibility. \n"]}, "PMC3658960_2": {"context": "However, these variants explain only \u223c5.7% of variance in disease susceptibility [1].\n", "support": ["Assuming a T2D population prevalence of 8%, these 63 newly discovered and established autosomal loci together account for 5.7% of variance in disease susceptibility, as calculated by transforming dichotomous disease risk onto a continuous liability scale20 (Online Methods).\n"]}, "PMC3658960_1": {"context": "According to the most recent meta-analysis of genome-wide association studies, 63 individual SNPs have now been linked with diabetes risk [1].\n", "support": ["Assuming a T2D population prevalence of 8%, these 63 newly discovered and established autosomal loci together account for 5.7% of variance in disease susceptibility, as calculated by transforming dichotomous disease risk onto a continuous liability scale20 (Online Methods).\n", "Figure 1 presents the distribution of Z-scores from Stage 2, aligned to the risk allele from Stage 1, at a subset of 3,412 independent (CEU r2 < 0.05) T2D replication variants that excludes lead SNPs and possible proxies (CEU r2 \u2265 0.1) at the 63 newly discovered and established loci represented on Metabochip.\n", "Using simulations, based on parameter estimates from this mixture model, we estimated that 488 (95% confidence interval (CI) 456\u2013521) of the independent replication SNPs, in addition to the 63 newly discovered and established loci, are associated with T2D susceptibility. \n"]}, "PMC3654344_1": {"context": "Currently, over 60 common risk variants have been identified [30\u201334], with a combined disease risk of 5\u201310% [34, 35], suggesting the existence of many more as yet undiscovered loci [34, 36, 37].\n", "support": ["Assuming a T2D population prevalence of 8%, these 63 newly discovered and established autosomal loci together account for 5.7% of variance in disease susceptibility, as calculated by transforming dichotomous disease risk onto a continuous liability scale20 (Online Methods).\n"]}, "PMC3654344_2": {"context": "A fundamental challenge facing those wishing to determine which of the genes in a particular locus is responsible for affecting disease risk, and dissect how this/these act, is the very scale of the problem (currently more than 500 genes in total to interrogate, with others emerging) [35]\n", "support": ["While such a model poses challenges for accumulating genome-wide significant evidence of association at a specific variant, it does suggest that genetic profiling based on the entirety of sequence variation has the potential to provide useful risk stratification for T2D.\n"]}, "PMC4076741_3": {"context": "The lead SNP for a putative secondary association signal (rs944801) is located within an intron of ANRIL (Morris et al., 2012).\n", "support": ["We detected two loci at which multiple independent association signals attained genome-wide significance: KCNQ1 (rs163184, P = 1.2 \u00d7 10\u221211; rs231361, P = 1.2 \u00d7 10\u22129; CEU r2 = 0.01) and CDKN2A/B (rs10811661, P = 3.7 \u00d7 10\u221227; rs944801, P = 2.4 \u00d7 10\u22129; CEU r2 = 0.01) (Fig. 2).\n", "Both signals at KCNQ1 have previously been reported in East Asian and European populations4,24. However, the secondary signal at CDKN2A/B, which maps to the non-coding CDKN2B-AS1 (ANRIL) transcript, has not previously been implicated in T2D susceptibility.\n"]}, "PMC3749360_3": {"context": "Increased incretin sensitivity improves \u03b2-cell function (13), thereby lowering T2D risk (10).\n", "support": ["The risk allele at ANK1 has features (nominally significant reduction in HOMA-B) indicating a primary effect on beta-cell function, whereas those at GRB14 and AKNRD55 are characteristic of loci acting primarily through insulin resistance (increased HOMA-IR) (Supplementary Fig. 10 and Supplementary Table 10).\n"]}, "PMC4030114_8": {"context": "The DIAGRAMv3 meta-analysis consisted predominantly of populations of European ancestry (12).\n", "support": ["To extend understanding of the genetic architecture and molecular basis of type 2 diabetes (T2D), we conducted a meta-analysis of genetic variants on the Metabochip involving 34,840 cases and 114,981 controls, overwhelmingly of European descent.\n", "To gain a more complete picture of patterns of trait overlap, we first assessed the effect of T2D risk alleles on glycemic traits in European-descent meta- analyses from the MAGIC Investigators (Online Methods). \n"]}, "PMC3749360_2": {"context": "Interestingly, the G allele had been previously associated with increased risk of type 1 diabetes (11) but lower risk of T2D (10).\n", "support": ["Finally\n"]}, "PMC3749360_1": {"context": "Of these SNPs, 66,000 were selected for efficient replication of top signals across multiple traits, with the hope that when tested in sufficiently large samples they might exceed genome-wide statistical significance (9,10)\n", "support": ["The T2D-nominated component of Metabochip comprises 21,774 variants, including 5,057 \u201creplication\u201d SNPs that capture the strongest, independent (CEU r2< 0.2) autosomal association signals from the GWAS meta-analysis conducted by the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. \n", "This genome-wide meta-analysis (\u201cDIAGRAMv3\u201d) includes data from 12,171 cases and 56,862 controls of European descent imputed up to 2.5 million autosomal SNPs, and augments the previously published \u201cDIAGRAMv2\u201d meta-analysis4 with four additional GWAS (Supplementary Table 1).\n"]}}, "PMC3522098": {"PMC3837041_3": {"context": "The stromal-vascular fraction (SVF) from fat depots of mice treated with EPO or saline was prepared and differentiated as described (20).\n", "support": ["METHODS\n"]}, "PMC3584060_1": {"context": "Interestingly, we found that Fndc5, the gene that codes for the recently discovered antidiabetic hormone irisin [39] was also significantly increased in Cox6a2 \u2212/\u2212 diaphragm (data not shown).\n", "support": ["Exercise benefits a variety of organ systems in mammals, and some of the best- recognized effects of exercise on muscle are mediated by the transcriptional coactivator PGC1\u03b1 Here we show that PGC1\u03b1 expression in muscle stimulates an increase in expression of Fndc5, a membrane protein that is cleaved and secreted as a new hormone, irisin. \n"]}, "PMC3618577_2": {"context": "Overexpression of irisin in the liver of mice, via adenoviral delivery, increases energy expenditure and reduces high fat diet-induced obesity.67\n", "support": ["Irisin is present in mouse and human plasma\n"]}}, "PMC3090745": {"PMC3369937_5": {"context": "we did find associations with cisSNPs for ABCA7, a novel AD risk locus gene [28]\n", "support": ["With our findings and those by Hollingsworth et al.12, there are now ten LOAD susceptibility loci (APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP, and ABCA7).\n"]}, "PMC3369937_3": {"context": "ABCA7, identified recently as a novel LOAD risk locus [28], [47], had significant cerebellar cisSNPs.\n", "support": ["Because Hollingworth et al.12 identified SNPs at ABCA7 as a novel LOAD locus, we included ABCA7 region SNPs in Stage 2 and provided the results to Hollingworth et al.12.\n"]}, "PMC3511432_1": {"context": "In recent efforts to identify additional genetic risk factors for LOAD, large-scale genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNP) in 10 genes: ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A6A, MS4A4E, and PICALM [5]\u2013[10].\n", "support": ["With our findings and those by Hollingsworth et al.12, there are now ten LOAD susceptibility loci (APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP, and ABCA7).\n"]}, "PMC3554198_1": {"context": "These are CLU, PICALM, CR1, BIN1, MS4A, ABCA7, CD33, EPHA1 and CD2AP (6\u201310).\n", "support": ["With our findings and those by Hollingsworth et al.12, there are now ten LOAD susceptibility loci (APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP, and ABCA7)\n"]}, "PMC3511432_2": {"context": "Recent large-scale LOAD GWAS have identified SNPs in ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A6A, MS4A4E, and PICALM [5]\u2013[10].\n", "support": ["With our findings and those by Hollingsworth et al.12, there are now ten LOAD susceptibility loci (APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP, and ABCA7).\n"]}, "PMC3511432_4": {"context": "several genes in the MS4A gene cluster have been identified in recent LOAD GWAS [9], [10]\n", "support": ["With our findings and those by Hollingsworth et al.12, there are now ten LOAD susceptibility loci (APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP, and ABCA7).\n"]}, "PMC3330267_2": {"context": "Examining the amount of genetic risk effect attributable to these genes (other than APOE), the most strongly associated single-nucleotide polymorphisms at each locus have population attributable fractions between 2.72 and 5.97%, with a cumulative population attributable fraction for non-APOE loci estimated to be as much as 35% (Naj et al., 2011).\n", "support": ["Examining the amount of genetic effect attributable to these candidate genes, the most strongly associated SNPs at each locus other than APOE demonstrated population attributable fractions (PAFs) between 2.72\u20135.97% (Supplemental Table 9), with a cumulative PAF for non-APOE loci estimated to be as much as 35%; however, these estimates may vary widely between studies22, and the actual effect sizes are likely to be much smaller than those estimated here because of the \u2018winner\u2019s curse\u2019. Also the results do not account for interaction among loci, and are not derived from appropriate population-based samples.\n"]}}, "PMC3650111": {"PMC3816614_2": {"context": "While TMAO could be derived from increased consumption of meat (Koeth et al., 2013), Prevotella has been previously associated with a dearth of meat in the diet (Wu et al., 2011).\n", "support": ["Of note, we observed a significant increase in baseline plasma TMAO concentrations in what historically was called enterotype 2 (Prevotella) (P < 0.05), a relatively rare enterotype that previously in one study was associated with low animal fat and protein consumption18.\n"]}}, "PMC3096954": {"PMC3262206_3": {"context": "To estimate the expression of the OTBC signature across the intrinsic molecular subtypes of breast cancer, we calculated the mean expression of both gene lists (that is, up- and downregulated) in the entire median-centered UNC337 dataset (n = 327) by using the subtype calls described in [6].\n", "support": ["In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features.\n", "Genomic studies have established four major breast cancer intrinsic subtypes (luminal A, Luminal B, HER2-enriched, basal-like) and a normal breast-like group that show significant differences in incidence, survival and response to therapy [1-3].\n"]}, "PMC3262206_2": {"context": "Hallmarks of these tumors include a high enrichment for a CD44+/CD24-/low TIC signature, a downregulation of cell junction proteins such as cadherins and claudins, an enrichment in mesenchymal markers, high lymphocyte infiltrations, and high phenotypic resistance to chemotherapy [6,11].\n", "support": ["More recently, a tumor initiating cell (TIC) genomic signature derived from CD44+/CD24-/low-sorted cells and mammospheres obtained from primary human breast tumors was found to be exclusively enriched by gene expression in the claudin-low subtype [6,7], and the expression of this CD44+/CD24-/low/claudin-low profile increased in posttreatment samples after neoadjuvant chemotherapy or hormone therapy [7].\n", "Thus, our data suggest that claudin-low tumors, compared with the other intrinsic breast tumor subtypes, are the most enriched for stem cell and/or TIC features, and on the basis of our vimentin immunofluorescence staining, it appears that these mesenchymal features are present within epithelial cells, which is a feature not seen in normal breast tissues.\n"]}, "PMC3262206_1": {"context": "Recent advances in the field suggest that breast tumors belonging to the claudin-low and basal-like intrinsic subtypes are particularly enriched in TIC cell signatures [6,7].\n", "support": ["More recently, a tumor initiating cell (TIC) genomic signature derived from CD44+/CD24-/low-sorted cells and mammospheres obtained from primary human breast tumors was found to be exclusively enriched by gene expression in the claudin-low subtype [6,7], and the expression of this CD44+/CD24-/low/claudin-low profile increased in posttreatment samples after neoadjuvant chemotherapy or hormone therapy [7].\n"]}, "PMC3262206_4": {"context": "High CD44high/CD24- ratios have been associated with the claudin-low breast cancer subtype [6,11].\n", "support": ["More recently, a tumor initiating cell (TIC) genomic signature derived from CD44+/CD24-/low-sorted cells and mammospheres obtained from primary human breast tumors was found to be exclusively enriched by gene expression in the claudin-low subtype [6,7], and the expression of this CD44+/CD24-/low/claudin-low profile increased in posttreatment samples after neoadjuvant chemotherapy or hormone therapy [7].\n"]}, "PMC3170246_6": {"context": "The immune status of mice may be particularly important when studying claudin-low tumors as one of the hallmarks of this tumor type is an increase in immune-related genes [7].\n", "support": ["Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features.\n"]}, "PMC3073183_1": {"context": "Recently, a subgroup of Basal-like tumors associated with poor prognosis has also been reported [4,5].\n", "support": ["In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype.\n", "Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation.\n", "In terms of prognosis, Kaplan-Meier survival analysis revealed that claudin-low tumors have a worse prognosis compared to luminal A tumors in both the UNC337 (hazard ratio [HR] of 2.83 and 5.66 for relapse-free survival [RFS] and overall survival [OS], respectively; P < 0.05) and NKI295 data sets (HR of 4.71 and 17.98 for RFS and OS, respectively; P < 0.001).\n", "Conversely, similar survival curves were observed between claudin-low tumors and the other poor prognosis subtypes such as luminal B, HER2-enriched and basal-like tumors (Figure 3b).\n", "These findings suggest that claudin-low tumors show some chemotherapy sensitivity but overall have a poor prognosis and may not be managed effectively with existing chemotherapy regimens.\n"]}, "PMC3170246_5": {"context": "Although a number of human tumor cell lines have been identified as sharing features of claudin-low tumors (MDA-MB-435, MDA-MB-436, Hs578T, BT549, MDA-MB-231, MDA-MB-157, SUM1315MO2, SUM159PT and HBL100), fewer claudin-low, murine mammary tumor cell lines have been established [7]\n", "support": ["In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype.\n"]}, "PMC3073183_2": {"context": "Context 130, a Basal-like context has under-expression of GATA3 which is in concordance with previous studies of Basal-like subgroup, \u2019claudin-low\u2019 with poor prognosis and more refractory to chemotherapy [5] .\n", "support": ["Results\n"]}, "PMC3170246_4": {"context": "These tumors have a prevalence of approximately 7-14% and a have a poor prognosis compared to luminal A tumors [7].\n", "support": ["Across all three databases, claudin-low tumors showed a prevalence of 7 to 14%, and were mostly ER-/PR-/HER2- (also known as triple-negative tumors, 61 to 71%).\n"]}, "PMC3170246_1": {"context": "Molecular profiling has identified 5 distinct subtypes of human breast tumors, luminal A, luminal B, HER2-enriched, basal-like and claudin-low [1-7].\n", "support": ["In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype.\n"]}, "PMC3170246_3": {"context": "Since claudin-low tumors possess features of stem cells [7], it is possible that the tumors that regress and recur or only partially regress are those that contain claudin-low cells.\n", "support": ["Second, we observed that claudin- low tumors compared to the other tumor subtypes, except for the normal breast- like group, showed the highest mRNA expression of ALDH1A1, which has recently been proposed to be another marker of breast stem cells and TICs [34] but also noted in stromal cells [24,34,35]. \n", "To further explore the potential enrichment for breast stem cells and TIC features, we evaluated the expression of three breast stem cell-like signatures [7,15,18] across the different subtypes.\n", "In this article, we characterize an important new disease group, namely the claudin-low subtype of breast cancer, and show that these tumors have a poor prognosis and features of mesenchymal and mammary stem cells.\n"]}, "PMC3170246_2": {"context": "Claudin-low tumors express mesenchymal genes such as Twist1, Twist2, Zeb1, Zeb2, Slug and Snail and low levels of E-cadherin and claudins 3, 4 and 7 [6,7].\n", "support": ["Consistent with this finding, we observed a high mRNA expression of known transcriptional repressors of E-cadherin such as SNAI1, SNAI2, TWIST1, TWIST2, ZEB1 and ZEB2, and other EMT-inducing factors such as hypoxia-inducible factor-1a in claudin-low tumors [31] (Figure 1b, Figure S2 in Additional file 1).\n"]}, "PMC3172243_4": {"context": "The MDA-MB-231 cell line used in this study was originally described as Basal B and has been recently characterized as Claudin-low [20], [21].\n", "support": ["These nine cell lines (MDA-MB-435, MDA-MB-436, Hs578T, BT549, MDA-MB-231, MDA-MB-157, SUM1315MO2, SUM159PT and HBL100) showed a gene expression pattern similar to the claudin-low tumor subtype with the lowest expression of genes involved in epithelial cell-cell adhesion (i.e., E-cadherin and claudins 3, 4 and 7), luminal differentiation (i.e., CD24, EpCAM) and high values for the CD44/CD24 and CD49f/EpCAM mRNA ratios (Figure S4, Table S3 in Additional file 1).\n"]}, "PMC3172243_5": {"context": "Claudin-low carcinomas and representative cell lines are characterized by a down-regulation of epithelial junction proteins, such as cadherins and claudins [20].\n", "support": ["Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features.\n"]}, "PMC3172243_7": {"context": "We also used available microarrays from the breast cancer cell lines [21], the UNC337-patient [20], the MERGE 550-patient dataset [47] and the NKI (295 patients [48], [49]).\n", "support": ["All microarray and patient clinical data are available in the University of North Carolina (UNC) Microarray Database [10] and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO:GSE18229 (referred to here as the UNC337 set).\n"]}, "PMC3216859_4": {"context": "The hypothesis that the cluster 1-samples are enriched for immature cells is further supported by the down-regulation of GATA3 seen in these samples compared to the cluster 2 samples (p = 3.8E-9), a protein that is also down-regulated in claudin-low samples [27].\n", "support": ["Compared to the luminal A, luminal B, HER2-enriched, and basal-like subtypes, claudin-low tumors showed inconsistent expression of basal keratins (keratins 5, 14 and 17) and low expression of HER2 and luminal markers such as ER, PR, GATA3, keratins 18 and 19 and the luminal gene cluster (Figure 1a).\n"]}, "PMC3172243_6": {"context": "CD44+/CD24- is considered a cancer stem cell or tumor initiating cell signature, and high CD44/CD24 ratios are characteristic of aggressive Claudin-low tumors and cell lines [20].\n", "support": ["More recently, a tumor initiating cell (TIC) genomic signature derived from CD44+/CD24-/low-sorted cells and mammospheres obtained from primary human breast tumors was found to be exclusively enriched by gene expression in the claudin-low subtype [6,7], and the expression of this CD44+/CD24-/low/claudin-low profile increased in posttreatment samples after neoadjuvant chemotherapy or hormone therapy [7].\n"]}, "PMC3172243_2": {"context": "Basal-like and Claudin-low carcinomas are mostly triple negative breast cancers (ER-PR-Her2-) associated with high resistance to chemotherapy and poor prognosis [20].\n", "support": ["Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation.\n"]}, "PMC3172243_1": {"context": "We next examined this signature across intrinsic breast cancer subtypes, using the UNC337 tumor database comprising 337 breast tumor cases [20].\n", "support": ["All microarray and patient clinical data are available in the University of North Carolina (UNC) Microarray Database [10] and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO:GSE18229 (referred to here as the UNC337 set).\n"]}, "PMC3216859_2": {"context": "we used previously published gene lists describing stroma [17,18], breast stem cells [15,19,31], myoepithelial cells [12,14], progenitor cells [14], mesenchymal cells [13], high-risk normal cells [16], epithelial cells from parous women [32], intrinsic genelist [5] and a genelist for prediction of the claudin-low subtype [27]\n", "support": ["All microarray and patient clinical data are available in the University of North Carolina (UNC) Microarray Database [10] and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO:GSE18229 (referred to here as the UNC337 set).\n"]}, "PMC3216859_3": {"context": "a gene list developed to classify the newly identified claudin-low subtype was used [27]\n", "support": ["All microarray and patient clinical data are available in the University of North Carolina (UNC) Microarray Database [10] and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO:GSE18229 (referred to here as the UNC337 set).\n"]}}, "PMC2958248": {"PMC4466270_1": {"context": "However, recent discoveries have shown that human conventional DCs (cDC) are generally capable of generating IFN-I responses to HIV-1, but HIV-1 seems to be able to escape from such cell-intrinsic immunity in most patients\n", "support": ["HIV replication is inefficient in DCs.\n", "IFN stimulation in pDCs appears to be triggered mostly by endocytosed virus, whose gRNA is recognized by TLR7 in endosomes37.\n"]}, "PMC4466270_2": {"context": "In addition to SAMHD1, cell-intrinsic immune responses in DCs are inhibited by the host protein TREX1, a host exonuclease that degrades HIV-1 reverse transcripts, which otherwise trigger microbial DNA sensors, leading to cell-intrinsic secretion of type I interferons [18,29].\n", "support": ["We did not examine whether TREX1 affects IFN production by pDCs, the major source of Type I IFNs during HIV infection.\n"]}, "PMC4466270_3": {"context": "enhancing their degradation [18,29],\n", "support": ["TREX1 metabolizes HIV RT products to suppress IFN induction\n"]}, "PMC5789701_1": {"context": "A similar delivery vehicle has previously been shown to selectively activate cGAS- and STING-dependent immune recognition pathways, which are involved in innate immune sensing of HIV-1 during natural infection [41].\n", "support": ["HIV DNA signals via STING, TBK1 and IRF3\n"]}, "PMC5789701_2": {"context": "mDCs from either HDs (n\u2009=\u20098) or ECs (n\u2009=\u20097) were cultured for 24\u00a0h in the presence of Poly I:C and 2\u00a0\u03bcg/mL of either ss- or ds-Gag DNA [41]\n", "support": ["TREX1 metabolizes HIV RT products to suppress IFN induction\n"]}, "PMC5635324_3": {"context": "In macrophages and T cells, cytosolic exonuclease TREX1 digests escaped HIV-1 DNA that would otherwise trigger innate DNA sensing (42)\n", "support": ["In Trex1\u2212/\u2212 mouse cells and human CD4+ T cells and macrophages in which TREX1 was inhibited by RNA interference, cytosolic HIV DNA accumulated, and HIV infection induced type I IFN that inhibited HIV replication and spreading.\n"]}, "PMC3250430_1": {"context": "cytosolic exonuclease TREX1 inhibits the innate immune response to HIV by degrading ssDNA derived from integrated provirus\n", "support": ["TREX1 metabolizes HIV RT products to suppress IFN induction\n"]}, "PMC3187686_3": {"context": "TREX1 was proposed to degrade cytosolic DNA resulting from HIV-1 reverse transcription, which would otherwise be capable of inducing an IFN response\n", "support": ["TREX1 bound to cytosolic HIV DNA and digested excess HIV DNA that would otherwise activate IFN expression via a TBK1, STING and IRF3 dependent pathway. HIV-stimulated IFN production in cells deficient in TREX1 did not involve known nucleic acid sensors.\n"]}, "PMC3187686_2": {"context": "TREX1 suppressed a type I IFN response that otherwise would be induced by HIV-1 infection\n", "support": ["TREX1 inhibits IFN production in response to HIV\n"]}, "PMC5635324_2": {"context": "This stealthy replication is in part dependent on the cytoplasmic exonuclease TREX1, which degrades HIV-1 reverse transcripts that would otherwise be sensed by cGAS leading to a type I IFN response (33, 42)\n", "support": ["TREX1 bound to cytosolic HIV DNA and digested excess HIV DNA that would otherwise activate IFN expression via a TBK1, STING and IRF3 dependent pathway.\n"]}, "PMC3250430_2": {"context": "the absence of TREX1, a type I IFN response is induced that inhibits HIV replication and spreading\n", "support": ["TREX1 inhibits IFN production in response to HIV\n"]}, "PMC5635324_1": {"context": "In this study TREX1 was suggested to digest unencapsidated HIV-1 DNA that would otherwise activate a type I IFN response in a STING-dependent manner.\n", "support": ["In Trex1\u2212/\u2212 mouse cells and human CD4+ T cells and macrophages in which TREX1 was inhibited by RNA interference, cytosolic HIV DNA accumulated, and HIV infection induced type I IFN that inhibited HIV replication and spreading.\n"]}, "PMC3250430_4": {"context": "this virus seems to be capable of efficiently evading these sensing systems.\n", "support": ["Productive HIV infection of macrophages and T cells, however, involves viral membrane fusion with the cell membrane and direct uncoating of the viral capsid into the cytosol, bypassing the endosomal compartment and TLR signaling.\n", "Some HIV DNA accumulated in the cytoplasm of HIV-infected cells, even when TREX1 is normally expressed, but did not activate IFN expression.\n"]}, "PMC5989071_1": {"context": "For example, depletion of the host cytosolic DNA exonuclease three prime repair exonuclease 1 (TREX1), a DNA exonuclease, increases the type I interferon (IFN) response to HIV and murine leukemia virus (MLV) infection (4, 8, 9).\n", "support": ["In Trex1\u2212/\u2212 mouse cells and human CD4+ T cells and macrophages in which TREX1 was inhibited by RNA interference, cytosolic HIV DNA accumulated, and HIV infection induced type I IFN that inhibited HIV replication and spreading.\n"]}, "PMC5989071_2": {"context": "it has been previously shown that TREX1 degrades ssDNA and dsDNA and DNA in RNA/DNA hybrids (8, 30, 31).\n", "support": ["TREX1 recognizes ssDNA or dsDNA with single strand overhangs \u2013 the kind of DNA in failed RT products.\n", "TREX1 might bind to HIV DNA nonspecifically in the cytosol, but as an exonuclease can only efficiently digest HIV DNA that contains broken ends or single strand overhangs.\n"]}, "PMC3142215_1": {"context": "The cellular exonuclease TREX1 was recently shown to bind and digest excess cytosolic HIV-1 DNA that would otherwise activate type I IFN expression and trigger an innate immune response\n", "support": ["TREX1 binds to transfected immunostimulatory DNA (ISD), and Trex1\u2212/\u2212 cells accumulate cytoplasmic DNA derived from endogenous retroelements, which activates interferon regulatory factor 3 (IRF3)-dependent IFN expression6,7.\n"]}, "PMC3142215_2": {"context": "Interestingly, similar to SAMHD1, TREX1 mutations in humans are associated with autoimmune and inflammatory diseases, including AGS\n", "support": ["TREX1 mutations are associated with inflammatory and autoimmune diseases, including Aicardi- Goutieres syndrome, chilblain lupus, and systemic lupus erythematosus (SLE), some of which have increased type I IFN3-5. \n"]}, "PMC4012220_2": {"context": "HIV-encoded cytosolic DNA produced by reverse transcription does not trigger a cell-autonomous interferon (IFN) or inflammatory response in activated CD4 T cells and macrophages, its primary targets\n", "support": ["The cytosolic exonuclease TREX1 suppressed IFN triggered by HIV.\n", "TREX1 bound to cytosolic HIV DNA and digested excess HIV DNA that would otherwise activate IFN expression via a TBK1, STING and IRF3 dependent pathway.\n"]}, "PMC4012220_1": {"context": "Since only a few copies of HIV DNA integrate, the bulk of HIV DNA remains in the cytosol unless cleared by host enzymes\n", "support": ["Few copies of HIV DNA integrate, leaving behind HIV DNA in the cytosol to be cleared by host enzymes.\n"]}, "PMC4012220_5": {"context": "The HIV-stimulated IFN response in Trex1-/- cells can be dampened by reverse transcriptase inhibitor (e.g., nevirapine) but not by integrase inhibitor (e.g., raltegravir), consistent with HIV DNA being the main pathogen associated molecular pattern (PAMP) detected by an innate immune sensor\n", "support": ["Nevirapine, which inhibits HIV reverse transcription, but not the IN inhibitor raltegravir, which acts after HIV DNA synthesis, inhibited IFN-\u03b2 and IL-6 expression in response to HIV in Trex1\u2212/\u2212 cells (Fig. 1e,f), suggesting that HIV reverse- transcribed DNA, rather than genomic RNA (gRNA), was triggering the response. \n"]}, "PMC4012220_4": {"context": "In the absence of TREX1, HIV infection triggers a robust type I IFN response strictly dependent upon the cytosolic DNA sensing pathway, including the endoplasmic reticulum (ER) localized adaptor stimulator of interferon genes (STING), TANK-binding kinase 1 (TBK1), and the transcription factor interferon regulatory factor 3 (IRF3)\n", "support": ["In Trex1\u2212/\u2212 mouse cells and human CD4+ T cells and macrophages in which TREX1 was inhibited by RNA interference, cytosolic HIV DNA accumulated, and HIV infection induced type I IFN that inhibited HIV replication and spreading.\n"]}, "PMC4012220_7": {"context": "Consequently, overall HIV-1 replication in which TREX1 expression is suppressed or ablated is reduced compared replication in normal cells, because DNA sensing results in expression of antiviral IFNs\n", "support": ["In Trex1\u2212/\u2212 mouse cells and human CD4+ T cells and macrophages in which TREX1 was inhibited by RNA interference, cytosolic HIV DNA accumulated, and HIV infection induced type I IFN that inhibited HIV replication and spreading.\n"]}}, "PMC3179858": {"PMC3142215_9": {"context": "SAMHD1-mediated HIV-1 restriction has so far been analyzed only in monocyte-derived DCs [9] and macrophages [10]\n", "support": ["Monocytes isolated from PBMCs by positive selection for CD14 using CD14 microbeads (Miltenyi Biotec Inc.) were differentiated into macrophages by culturing in DMEM supplemented with 10% heat inactivated foetal bovine serum (FBS), 10 ng/ml Macrophage-Colony Stimulating Factor (M-CSF, R&D Systems) for the first 2 days and 20 ng/ml thereafter, in 24 well plates at 3.0-3.5\u00d7105 cells/well.\n"]}, "PMC3234228_6": {"context": "we confirm the effect of the proteasome inhibitor MG132 on the reversibility of Vpx-mediated degradation of SAMHD1 [19], [20].\n", "support": ["Importantly, the effect of Vpx was blocked when macrophages were exposed to the proteasome inhibitor MG132 prior to and during infection with Vpx-loaded SIV VLP (Figure 3b).\n"]}, "PMC3142215_8": {"context": "HIV-1 Vpr does not interact or degrade SAMHD1 [10].\n", "support": ["As a negative control we selected the Vpr accessory proteins of HIV-1 and SIVmac, because they are closely related to Vpx, sharing roughly 25% and 50% amino acid identity, and can load cellular substrate proteins onto CRL4DCAF1,(21) but, unlike Vpx, Vpr does not alleviate the inhibition of lentivirus infection in MDM.\n", "SAMHD1 co-precipitated efficiently with both Vpx variants, but not with Vpr (Figure 2b).\n", "SAMHD1 was co-expressed with wild type SIVmac Vpx, a VpxQ76A variant that does not bind DCAF1, or HIV-1 Vpr that does not bind SAMHD1, in HEK 293T cells. \n"]}, "PMC3142215_6": {"context": "It might be possible that SAMHD1 acts in concert with another myeloid-specific co-factor [10].\n", "support": ["One possible explanation is that SAMHD1-mediated restriction may require a myeloid cell-specific molecule.\n"]}, "PMC3178557_3": {"context": "Contrarily to A3A, SAMHD1 is expressed in cells other than myeloid cells, as its isolation from HEK 293T cells indicates [59].\n", "support": ["Specifically, we directed the assembly of three sets of protein complexes in HEK 293T cells for their subsequent proteomic characterization (Figure 2a)\n", "SAMHD1 was co-expressed with wild type SIVmac Vpx, a VpxQ76A variant that does not bind DCAF1, or HIV-1 Vpr that does not bind SAMHD1, in HEK 293T cells. \n", "SAMHD1 is expressed in HEK 293T cells, undifferentiated THP-1 cells and other non-myeloid cell types that do not possess a Vpx-sensitive mechanism restricting primate lentivirus infection (Supplementary Figures 6 and 7).\n"]}, "PMC3230851_1": {"context": "Recent studies have identified a host SAM-domain HD-domain containing protein 1 (SAMHD1) as a target for Vpx-mediated proteosomal degradation, which overcomes a post-entry block to reverse transcription in myeloid cells [158,159].\n", "support": ["Vpx relieves the inhibition of lentivirus infection in macrophages by loading SAMHD1 onto the CRL4DCAF1 E3 ubiquitin ligase, leading to highly efficient proteasome- dependent degradation of the protein. \n", "The Vpx accessory protein of HIV-2/SIVsm lineage viruses removes this inhibition by targeting SAMHD1 for proteasome-dependent degradation via CRL4DCAF1 E3 ubiquitin ligase (Supplementary Figure 5).\n"]}, "PMC3142215_7": {"context": "It appears that only Vpx from the SIVsm/HIV-2 lineage counteracts SAMHD1-mediated HIV-1 restriction in myeloid cells [9,10]\n", "support": ["In contrast, HIV-2 and related simian immunodeficiency viruses (SIVsm/mac) transduce myeloid cells efficiently owing to their virion-associated Vpx accessory proteins, which counteract the restrictive mechanism5,6.\n", "Of note, we observed that SAMHD1 levels are depleted by Vpx in both MDM and monocyte- derived dendritic cells in a Vpx glutamine Q76 dependent manner (data not shown) implicating SAMHD1 as the key AGS protein inhibiting lentivirus infection in myeloid cells. \n"]}, "PMC3142215_5": {"context": "Together, these studies suggested that SAMHD1 is the myeloid-cell specific HIV-1 restriction factor counteracted by Vpx [9,10] (Figure 1).\n", "support": ["SAMHD1 is expressed in HEK 293T cells, undifferentiated THP-1 cells and other non-myeloid cell types that do not possess a Vpx-sensitive mechanism restricting primate lentivirus infection (Supplementary Figures 6 and 7).\n", "One possible explanation is that SAMHD1-mediated restriction may require a myeloid cell-specific molecule.\n"]}, "PMC3178557_1": {"context": "Despite the fact that SAMHD1 is expressed in different cell types, it seems to restrict lentiviral infection specifically in myeloid cells, probably highlighting the need for a particular cellular context, or for specific cellular partners [59], [60].\n", "support": ["Of note, we observed that SAMHD1 levels are depleted by Vpx in both MDM and monocyte- derived dendritic cells in a Vpx glutamine Q76 dependent manner (data not shown) implicating SAMHD1 as the key AGS protein inhibiting lentivirus infection in myeloid cells. \n", "SAMHD1 is expressed in HEK 293T cells, undifferentiated THP-1 cells and other non-myeloid cell types that do not possess a Vpx-sensitive mechanism restricting primate lentivirus infection (Supplementary Figures 6 and 7).\n"]}, "PMC3230851_2": {"context": "SAMHD1 [158], like the exonuclease TREX1 [160] may be responsible for innate sensing of viral DNA, and viral targeting of SAMHD1 may possibly contribute to viral innate immune evasion, although this has not been specifically addressed\n", "support": ["Whether SAMHD1 functions autonomously, what are the other key components of a putative SAMHD1 pathway, and what are the salient features of SAMHD1 that endow this protein with anti-HIV activity, requires further investigation.\n", "One unanswered question is how myeloid cell specificity of SAMHD1-mediated inhibition of HIV-1 infection is achieved?\n", "This evidence clearly demonstrates that SAMHD1 inhibits MDM infection by HIV-1 and other primate lentiviruses by disrupting synthesis of viral cDNA.\n"]}, "PMC3142215_4": {"context": "Further analysis revealed that SAMHD1 blocks HIV-1 reverse transcription, as silencing SAMHD1 in THP-1 cells [9] and macrophages [10] increases the levels of viral DNA.\n", "support": ["In summary, our results show that SAMHD1 interferes with HIV infection of macrophages by preventing efficient viral cDNA synthesis.\n", "The Vpx accessory protein of HIV-2/SIVsm lineage viruses removes this inhibition by targeting SAMHD1 for proteasome-dependent degradation via CRL4DCAF1 E3 ubiquitin ligase (Supplementary Figure 5).\n", "Our discovery that the SAMHD1 protein inhibits HIV infection in macrophages unveils a novel and unexpected link between unconventional cell-intrinsic innate immune mechanisms and the anti-viral defence.\n", "Specifically, it can be clearly seen that the \u201cearly\u201d (\u201cE\u201d) vs. \u201clate\u201d (\u201cL\u201d) cDNA PCR readouts showed selective repression of \u201clate\u201d reverse transcription products at high but not low SAMHD1 levels.\n"]}, "PMC3142215_1": {"context": "By contrast, Hrecka and colleagues identified SAMHD1 from HEK 293T cells expressing tagged Vpx in a proteomic screen using multidimensional protein identification technology [10].\n", "support": ["All protein complexes were purified by two sequential immunoprecipitations of epitope tags, under native conditions, and their subunit composition was analyzed by Multidimensional Protein Identification Technology (MudPIT)18.\n"]}, "PMC3142215_3": {"context": "Both studies confirmed that Vpx interacts with SAMHD1 and induces proteasomal degradation of SAMHD1 in THP-1 cells or macrophages, which can be restored by treatment with a proteasome inhibitor [9,10].\n", "support": ["Since HIV-2 and related simian viruses have evolved the Vpx function to counteract SAMHD1, they are able to infect macrophages much more readily than HIV-1.\n", "Human epitope-tagged SAMHD1 was co-expressed with Vpx, or Vpr, in HEK 293T cells and Vpx/Vpr immune complexes were analyzed by Western blotting.\n", "SAMHD1 co-precipitated efficiently with both Vpx variants, but not with Vpr (Figure 2b).\n", "SAMHD1 was co-expressed with wild type SIVmac Vpx, a VpxQ76A variant that does not bind DCAF1, or HIV-1 Vpr that does not bind SAMHD1, in HEK 293T cells. \n", "We conclude that Vpx specifically binds to, and recruits SAMHD1 to the DCAF1-DDB1 module of CRL4DCAF1 E3 ubiquitin ligase.\n"]}, "PMC3142215_2": {"context": "They demonstrated that Vpx relieves the inhibition of HIV-1 infection in monocyte-derived macrophages by mediating proteasome-dependent degradation of SAMHD1 through the CUL4A/DCAF1 E3 ubiquitin ligase [10].\n", "support": ["Vpx relieves the inhibition of lentivirus infection in macrophages by loading SAMHD1 onto the CRL4DCAF1 E3 ubiquitin ligase, leading to highly efficient proteasome- dependent degradation of the protein. \n"]}, "PMC3205391_2": {"context": "Viral particle-associated Vpx protein induces a proteasome-dependent degradation of SAMHD1 in the target cell very early after entry [126,127].\n", "support": ["Vpx relieves the inhibition of lentivirus infection in macrophages by loading SAMHD1 onto the CRL4DCAF1 E3 ubiquitin ligase, leading to highly efficient proteasome- dependent degradation of the protein. \n", "The Vpx accessory protein of HIV-2/SIVsm lineage viruses removes this inhibition by targeting SAMHD1 for proteasome-dependent degradation via CRL4DCAF1 E3 ubiquitin ligase (Supplementary Figure 5).\n"]}}, "PMC3607626": {"PMC3297570_1": {"context": "This network analysis led to the identification of specific co-expression modules that are differentially expressed in ASD and controls [20].\n", "support": ["Here, we demonstrate consistent differences in transcriptome organization between autistic and normal brain by gene co-expression network analysis.\n"]}, "PMC3297570_2": {"context": "These included a neuronal module that was enriched for genes with low GWAS P-values, suggesting that the differential expression of this module between cases and controls reflects a causal relationship [20].\n", "support": ["These results indicate that (a) M12 consists of a set of genes that are supported by independent lines of evidence to be causally involved in ASD pathophysiology, and (b) the upregulation of immune response genes in the autistic brain observed by us and others25 has no evidence of a common genetic component.\n", "Moreover, using a published autism GWAS dataset, we show that the neuronal module is enriched for genetically associated variants, providing independent support for the causal involvement of these genes in autism.\n"]}, "PMC3174192_1": {"context": "To date, a number of studies have investigated gene expression in ASD (for review see [29]), with three examining ASD brain tissue on a genome-wide scale [30], [31], [32].\n", "support": ["As a negative control, we performed the same set-enrichment analysis using two GWAS studies for non-psychiatric disease performed on the same genotyping platform: a genome-wide association for hair color23, and a GWAS study of Warfarin maintenance dose24 finding no significant enrichment of the association signal (Figure 4b, Supplementary Figure 4).\n", "Moreover, using a published autism GWAS dataset, we show that the neuronal module is enriched for genetically associated variants, providing independent support for the causal involvement of these genes in autism.\n", "In contrast, the immune-glial module showed no enrichment for autism GWAS signals, indicating a non-genetic etiology for this process.\n"]}, "PMC3174192_3": {"context": "The most comprehensive transcriptomics study of ASD post-mortem brain to date (Voineagu et al) concludes that one of two significant co-expression networks is involved in immune function [32].\n", "support": ["The genome-wide analysis performed here significantly extends previous findings implicating synaptic dysfunction, as well as microglial and immune dysregulation in ASD6 by providing an unbiased systematic assessment of transcriptional alterations and their genetic basis.\n", "We show that the transcriptome changes observed in ASD brain converge with GWAS data in supporting the genetic basis of synaptic and neuronal signaling dysfunction in ASD, while immune changes have a less pronounced genetic component and thus are most likely either secondary phenomena or caused by environmental factors.\n", "Since immune molecules and cells such as microglia play a role in synaptic development and function26, we speculate that the observed immune up- regulation may be related to abnormal ongoing plasticity in ASD brain. \n"]}}}